Doug Ingram, Sarepta CEO (Sarepta Therapeutics)
Sarepta reveals positive results in limb-girdle gene therapy trial. What does that mean for DMD?
Sarepta on Monday unveiled a small batch of positive data for one of the gene therapies it bought out last year, sketching a path toward …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
